natgillin/translations-raw huggingface dataset:
A method for treating adult respiratory distress syndrome, shock, oxygen toxicity, multiple organ injury syndrome secondary to septicemia, multiple organ injury syndrome secondary to trauma, reperfusion injury of tissue due to cardiopulmonary bypass, myocardial infarction, acute glomerulonephritis, vasculitis, reactive arthritis, dermatosis with acute inflammatory components, stroke, thermal injury, hemodialysis, leukapheresis, necrotizing enterocolitis or granulocyte transfusion associated syndrome, psoriasis, organ/tissue transplant rejection, graft vs, host reaction, Raynaud's syndrome, autoimmune thyroiditis, dermatitis, multiple sclerosis, rheumatoid arthritis, insulin-dependent diabetes mellitus, uveitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis or systemic lupus erythematosus or asthma in a patient which comprises administering to said patient a therapeutically effective amount of a compound in accordance with claim 1, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, naznačen time, da se upotrebljava kao lijek za liječenje sljedećih stanja: sindrom respiratornog poremećaja kod odraslih, šok, toksičnost kisika, sindrom višestruke ozljede organa kao sekundarno stanje nakon septikemije, sindrom višestruke ozljede organa kao sekundarno stanje nakon traume, reperfuzijska ozljeda tkiva zbog kardiopulmoname premosnice, infarkt miokarda, akutni glomerulonefritis, vaskulitis, reaktivni artritis, dermatoza s akutnim upalnim komponentama, udar, termalna ozljeda, kemodijaliza, leukafereza, nekrotizirajući enterokolitis ili sindrom povezan s granulocitnom transfuzijom, psorijaza, odbijanje presađenog organa/tkiva, reakcija usatka protiv stanice domaćina, autoimuna bolest, Raynaudov sindrom, autoimuni tiroiditis, dermatitis, multipla skleroza, reumatoidni artritis, dijabetes mellitus ovisan o inzulinu, uveitis, upalna bolest crijeva, Chronova bolest, ulcerativni kolitis ili sistemska lupus eritematoza ili astma. 11) -COCH;,
(2005) Association of the serotonin transporter gene polymorphism with Korean male alcoholics. 
Tegije 5-HTTLPR povezane s prijenosnikom serotonina gena za prijenosnik serotonina SLC6A4.
The hand wand of Statement, further comprising a third transducer module configured to apply ultrasonic therapy to a third layer of tissue, wherein the third layer of tissue is at a different depth than the first or second layers of tissue. 
Sustav za kozmetičko snimanje i liječenje (20) u skladu s patentnim zahtjevom 1, koji dodatno podrazumijeva treći modul sonde (200 "), konfiguriran za primjenu ultrazvučne terapije na treći sloj tkiva, naznačen time, da je treći sloj tkiva na različitoj dubini od prvog ili drugog sloja tkiva.
Also provided is a kit that includes a compound of Formula I, or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers or tautomer thereof. 
2. < Spoj sukladno patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, farmaceutski prihvatljiv kokristal, stereoizomer, mješavina stereoizomera ili tautomer, naznačeno time što R? je H.
ii) imagery data that is representative of at least one visual imagery, iii) audio data that is representative of at least one audio recording; and 
zadani broj alfanumeričkih znakova, ii) slikovne podatke koji predstavljaju najmanje jedan slikovni prikaz, iii) zvučne podatke koji predstavljaju najmanje jednu zvučnu snimku; i iv) bilo koju njihovu kombinaciju.
No. 129,464 A/CUNNINGHAM refers to the general construction of the beehive and not to a lid that opens and therefore is irrelevant to my invention. 
US 129464/ CUNNINGHAM se odnosi općenito na konstrukciju košnice, a ne na poklopac koji se otvara i stoga nije važan za moj izum.
Identification assembly according to any of the preceding claims, wherein the second laser produced image (21) corresponds to the first image (19). 
Sklop za identifikaciju prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu druga laserski producirana slika (21) odgovara prvoj slici (19).
the total number of the intermediate electrodes equaled 50; 
Broj objave europskog patenta:
The catheter as claimed in any preceding claim, wherein the catheter has a diameter in the range 3.3 to 4.6mm (10 to 14 F). 
Kateter prema bilo kom od prethodnih zahtjeva, pri čemu kateter ima promjer u rasponu od 3,3 do 4,6 mm (10 do 14 F).
By extension, the data support the hypothesis that enteric-coating an active tablet will reduce, or eliminate, the abnormal smell which would otherwise be produced by the active in vivo. 
Kao nastavak, podaci podržavaju hipotezu da će enteričko oblaganje aktivne tablete smanjiti, ili eliminirati, abnormalni miris koji bi inače proizvela aktivna tvar in vivo.
The system of claim 7, wherein a vapor fraction from the high temperature/high pressure separator is fed to the fixed bed hydroconversion reactor system. 
Sustav u skladu s patentnim zahtjevom 26, naznačen time, da se parna frakcija iz separatora (80) visoke temperature / visokog tlaka dovodi u reaktorski sustav hidrokonverzije sa fiksnim slojem (14).
the suffix bitstring of a last coefficient location is generated by performing binarization on a suffix of the symbol of the last coefficient location according to a fixed-length binarization scheme, wherein a range of a value of the prefix of the symbol is determined based on a size of the transformation block and a range of a value of the suffix of the symbol is determined based on the value of the prefix of the symbol, and 
aritmetički dekoder koji je konfiguriran za provođenje kontekstnog aritmetičkog dekodiranja na prefiksu niza bitova mjesta zadnjeg značajnog koeficijenta između informacija o mjestu zadnjeg značajnog koeficijenta, i, kada je prefiks niza bitova veći od prethodno određene vrijednosti, provođenje zaobilaznog načina aritmetičkog dekodiranja na sufiksu niza bitova mjesta zadnjeg značajnog koeficijenta između informacija o mjestu zadnjeg značajnog koeficijenta;
Use of the formulation of embodiment 1 in the manufacture of a medicament for treating an infection in a subject. 
Oralna formulacija u obliku tablete u skladu s patentnim zahtjevom 1, naznačena time što tableta dodatno sadrži sredstvo za klizanje.
The method of claim 12, wherein the at least one gelling agent of the pharmaceutical composition is a hydroxypropylcellulose. 
komplet dodatno uključuje treći spremnik koji sadrži najmanje jedno sredstvo za želiranje; ili API je spoj predstavljen sljedećom strukturnom formulom
The compound of any one of claims 1 to 6 wherein: 
Spojevi iz bilo kojeg od zahtjeva od 1 do 6 gdje:
All parts having contact with the beverage are thus for single use only. 
Svi dijelovi koji imaju dodir s pićem se stoga, dakle, upotrebljavaju samo jednom.
Lactoferrin or a nucleic acid molecule encoding same, for use in the diagnosis or prognosis of Alzheimer's disease. Lactoferrin for use according to claim 1, in which said diagnosis or prognosis is performed in a biological sample of a subject selected from mucous tissue and saliva. 
Uporaba laktoferina ili molekula nukleinske kiseline koja kodira isti, u dijagnozi ili prognozi Alzheimerove bolesti u biološkom uzorku dobivenom od subjekta izabranog od mukoznog tkiva i sline.
The method according to claim 1, wherein the compound is selected from the group consisting of a compound of formula (I-C) or formula (I-D) 
Farmaceutski spoj sastoji se od spoja formula (I-A) ili (I-B) kao što je navedeno u bilo kojem od zahtjeva 1- 16.
A method of preparing a pharmaceutical composition, said method comprising admixing a GPR119 agonist, a DPP-IV inhibitor and one or more other pharmaceutically or physiologically acceptable compound selected from the group consisting of: alpha-glucosidase inhibitor, sulfonylurea, meglitinide, alpha-glucosidase inhibitor, thizaolidinedione, biguanide, insulin analog and chromium picolinate/biotin, together with at least one pharmaceutically acceptable carrier, wherein said DPP-IV inhibitor is not identical to 1-[2-[5-cyanopyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine (NVP-DPP728). 
Postupak priprave farmaceutskog pripravka, naznačen time, da navedeni postupak obuhvaća miješanje GPRI19 agonista i DPP-IV inhibitora skupa s barem jednom farmaceutski prihvatljivom podlogom, pri čemu navedeni DPP- IV inhibitor nije identičan s 1-[2-[(5-cijanopiridin-2-iljamino jetilamino |acetil-2-cijano-(S)-pirolidinom (NVP- DPP728).
The pyridone derivative, or a salt thereof, according to any of (1) to (4), wherein R3 in the formula (I) represents a hydrogen atom, a fluorine atom, or a methyl group. 
Derivat piridona ili njegova sol prema patentnim zahtjevima 1 do 4, naznačen time da je R* u formuli (I) atom vodika, atom fluora ili metil grupa.
comparing the amount of said immunologic complex before and after onset of the treatment, wherein a decrease in the amount of said immunologic complex indicates that said subject has a high potential of being responsive to the treatment. 
(e) uspoređivanja količine navedenog imunološkog kompleksa prije i nakon početka liječenja, gdje smanjivanje količine navedenog imunološkog kompleksa ukazuje da subjekt ima veliki potencijal da reagira na liječenje.
determining if the temperature of the chamber exceeds an upper threshold of the steady state range. 
određivanje (1102) stanja u kojem temperatura u komori prelazi gornju granicu raspona ravnomjernog stanja.
The vaccine of claim 2, wherein the hapten conjugated to a carrier protein is nicotine or a nicotine-like molecule conjugated to diphtheria toxoid or a derivative thereof. 
Cjepivo u skladu s patentnim zahtjevom 2, naznačeno time što je hapten konjugiran s proteinskim nosačem nikotin ili nikotinu slična molekula, konjugirana s difterijskim toksoidom ili njegovim derivatom.
Suitable sugars and sugar alcohols for use according to the invention include non-crystallising or treated forms of dextrose, maltose, sucrose, fructose, glucose syrup, invert sugar syrup, honey, laevulose, sorbitol, xylitol, maltitol, mannitol and isomalt. 
Pogodni šećeri i šećerni alkoholi za uporabu prema izumu obuhvaćaju ne-kristalizirajuće 1li tretirane oblike dekstroze, maltoze, saharoze, fruktoze, glukoznog sirupa, sirup invertovanog šećera, med, fruktozu, sorbitol, ksilitol, maltitol, manitol 1 izomaltitol.
The process according to any one of the preceding claims, characterized in that the polymer material provided in step (b) comprises a recycled polymer material, wherein the recycled polymer material preferably comprises a micronized recycled polymer material. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da polimerni materijal osiguran u koraku (b) sadrži reciklirani polimerni materijal.
A pharmaceutical composition comprising a first and second pharmaceutically effective therapeutic agent, wherein the first agent is the antibody of claim 1, and the second agent is selected from the group consisting of: a chemotherapeutic agent, an angiogenesis inhibitor and an anti-tumor agent. 
Farmaceutski pripravak koji sadrži prvo i drugo farmaceutski učinkovito terapeutsko sredstvo, naznačen time da prvo sredstvo je protutijelo ili fuzijski protein protutijela kako je navedeno u zahtjevima 1 do 9, a drugo sredstvo je odabrano iz skupine koja sadrži: kemoterapijsko sredstvo, inhibitor angiogeneze i anti-tumorsko sredstvo proizvoljno zajedno sa farmaceutski prihvatljivim nosačem, otapalom ili pomoćnim sredstvom.
The inner boot of claim 2, wherein said bellows band is made of plastic material. 
Unutarnja čizma prema jednom ili više prethodnih zahtjeva, naznačena time, da je spomenuta rastezna traka (14) izrađena od plastičnog materijala.
D represents a non steroidal anti-inflammatory subunit or a steroid subunit or a pharmaceutically acceptable salt or solvate thereof; 
D predstavlja nesteroidnu protuupalnu podjedinicu ili stereidnu podjedinicu, ili njenu farmaceutski prihvatljivu sol ili solvat; 35
The ultrasonic magnetostrictive radiator 4 is made in the form of a hollow cylinder, whose inside diameter matches the inside diameter of OWT 5 . 
Ultrazvučni magnetostriktivni radijator 4 je napravljen u obliku šupljeg cilindra čiji je unutarnji promjer jednak unutarnjem promjeru CNI-a 5.
Materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used. 
Materijali upotrijebljeni za pripravljanje tih različitih pripravaka trebaju biti farmaceutski čisti i netoksični u upotrijebljenim količinama.
The composition according to claim 1, wherein said glaucoma is selected from the group consisting of primary open-angle glaucoma, primary angle-closure glaucoma, secondary open-angle glaucoma, secondary angle-closure glaucoma, pigmentary glaucoma, neovascular glaucoma, pseudophakic glaucoma, malignant glaucoma, uveitic glaucoma, glaucoma due to peripheral anterior synechia, and combinations thereof. 
Pripravak prema patentnom zahtjevu 1, naznačen time da je spomenuta glaukoma izabrana iz skupine koja sadrži primarnu glaukomu otvorenog kuta, primarnu glaukomu zatvarajućeg kuta, sekundarnu glaukomu otvorenog kuta, sekundarnu glaukomu zatvarajućeg kuta, pigmentarnu glaukomu, neovaskularnu glaukomu, pseudopakičnu glaukomu, zloćudnu glaukomu, uvejsku glaukomu, glaukomu uzrokovanu sinehijom perifernog anteriora, te njihove kombinacije.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) ciprodinil.
thiomorpholinyl, piperidinyl, pyrrolidinyl, and morpholinyl; wherein said piperidinyl, and pyrrolidinyl are optionally substituted with CF3, CH2F, CH2CH2F, C(1-2)alkyl (including CH3), —CN, OH, or CH2OH, and up to three additional substituents selected from the group consisting of CH3, and F (including difluoropiperidinyl, fluoropiperidinyl); 
o LAI domarfolii, piperidinil, pirolidinil, i morfolinil; pri čemu su navedeni piperidinil | i pirolidinil proizvoljno supstituirani s CF3, CH>F, CHoCHbF, Ca-alkil, -CN, OH, ili CH2OH, 1 do tri dodatna supstituenta odabrana iz skupine koju čine CH-, i F;
a heavy chain human subgroup III consensus framework sequence having a substitution at position 48, 67, 69, 71, 73 and/or 78, optionally V48I, F67A, I69F, R71A, N73T and/or L78A. 
humana podskupina III jakog lanca konsenzualne okosnice sekvenci, koja ima supstituciju na poziciji 48, 67, 69, 71, 73 i/ili 78, opcijski V48I, F67A, I69F, R71A, N73T i/ili L78A.
The cryptographic-key field overlaps any portion of the first operand. 
(32) Datum podnošenja prve prijave: 24.06.2010.
blending the opioid agonist and the third hydrophobic material to form a mixture; heating the mixture to a temperature sufficient to at least soften the mixture; extruding the mixture to form a strand; and 
Farmaceutski proizvod prema bilo kojem od prethodnih zahtjeva, naznačen time da su čestice opioidnog antagonista oblikovane: a) miješanjem opioidnog antagonista i prvog hidrofobnog materijala tako da formiraju smjesu; b) zagrijavanjem smjese na temperaturu dovoljnu barem da omekša smjesu; Cc) ekstrudiranjem smjese tako da nastaje lanac, i d) rezanjem lanca u čestice.
In some illustrative, but not limiting, embodiments of this invention, pH adjustment is accomplished with a phosphate buffer. 
U nekim ilustrativnim, ali neograničavajućim, varijantama ovog izuma, podešavanje pH vrijednosti se postiže fosfatnim puferom.
In this case it is particularly advantageous to provide for the cell code to be univocal for the whole magazine; in fact, in this way it is not possible to confuse the cells with one another. 
U ovom slučaju je naročito povoljno to, da se osigura takav kod ćelije koji je jednoznačan za cijeli spremnik; u stvari, na taj način ne može doći do zamjene ćelija jedne s drugom.
is independently selected from: halogen, C1-4 alkyl and C1-4 alkoxy; alternatively, R6 and R7, together with the carbon atoms to which they are attached, combine to form a 6-membered carbocyclic ring; 
R' je nezavisno odabrano od: halogen, C,u alkil i C,4 alkoksi; alternativno, RiR', zajedno sa ugljikovim atomima za koje su oni vezani, se kombiniraju da formiraju 6-očlami karbociklični prsten;
A polypeptide comprising SEQ ID NO 8, more preferably a sequence from the group comprising SEQ ID NO6, SEQ ID NO7, SEQ ID NO8, SEQ ID NO9 and SEQ ID NO10, more preferably SEQ ID NO6, most preferably Ara h 7 isotype 7.0201 or a variant thereof, wherein the polypeptide is recombinant, immobilized purified or a fusion protein, preferably purified and recombinant and immobilized. A use of the polypeptide according to claim 12, the carrier according to any of claims 1 to 2 or the kit according to any of claims 3 to 4 for the diagnosis of peanut allergy, wherein preferably the sensitivity of the diagnosis is increased. 
Uporaba polipeptida koji sadrži SEQ ID NO 8, poželjnije sekvence iz skupine koja sadrži SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8, SEQ ID NO 9 i SEQ ID NO 10, poželjnije SEQ ID NO 6, najpoželjnije Ara h 7 izotip 7.0201 ili njegova varijanta koja se veže na protutijelo na Ara h 7 izotip 7.0201 od subjekta alergičnog na kikiriki, pri čemu je polipeptid rekombinantni, imobilizirani pročišćeni ili fuzijski protein, poželjno pročišćeni i rekombinantni i imobilizirani, naznačena time što je za proizvodnju kompleta za dijagnozu alergije na kikiriki.
The composition according to any of claims 1-29, wherein the PTH is included at a concentration selected from 1 mg/ml to 10 mg/ml, 1 mg/ml to 5 mg/ml, 1 mg/ml to 3 mg/ml, and 1 mg/ml to 2 mg/ml. 
Sastav prema bilo kojem zahtjevu 1 do 5, naznačen time, da sadrži PTH u koncentraciji od 1,4 mg/ml, metionin u koncentraciji od 2 mg/ml, poloksamcr u koncentraciji od 0,3 mg/ml, i fiziološki prihvatljivo pufersko sredstvo koje održava pH formulacije na pH 5,5.
The composition of Claim 2, additionally comprising a second therapeutic agent selected from a second HIV protease inhibitor, a non-nucleoside reverse transcriptase inhibitor, a nucleoside/nucleotide reverse transcriptase inhibitor, a viral entry inhibitor, an integrase inhibitor, an immune based antiretroviral agent, a viral maturation inhibitor, a cellular inhibitor, or combinations of two or more of the above. 
Kompozicija prema zahtjevu 7 ili zahtjevu 8, koja dodatno sadrži drugo terapeutsko sredstvo koje se bira od drugog inhibitora HIV proteaze, nenukleozidnog inhibitora reverzne transkriptaze, nukleozid-nog/nukleotidnog inhibitora reverzne transkriptaze, inhibitora ulaza virusa, inhibitora integraze, antiretroviralnog imunološkog sredstva, inhibitora sazrijevanja virusa, staničnog inhibitora, ili od kombinacija dva ili više gore navedenih.
A process for preparing a compound as claimed in claim 1, the process comprising the following steps: by reacting a compound of formula (XIV): 
Postupak dobivanja spoja u skladu s patentnim zahtjevom 1, naznačen time što se navedeni postupak sastoji u sljedećim koracima:
the infection is caused by an organism resistant to tigecycline; 
(m) infekcija je uzrokovana organizmom otpornim na tigeciklin;
Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines. 
Liposomi se mogu dobiti od raznih fosfolipida, kao što su kolesterol, stearilamin ili fosfatidilkolini.
The method according to claim 1 or 2, wherein said protective overlay (1) is a powder based overlay (1a), and wherein the method further comprises applying a paper overlay (1b) on the powder based overlay (1a). 
Postupak prema zahtjevu 1 ili 2, naznačen time što je navedeni zaštitni sloj prevlake (1) zaštitni sloj temeljen na prahu (1a), te pri čemu postupak nadalje obuhvaća nanošenje papirnog sloja (1b) na sloj prevlake temeljen na prahu (1a).
The cells or article of manufacture for use according to claims 1 or 2 wherein at least 10 % of said adherent cells are at a proliferative phase. 
Stanice ili proizvodni artikl, namijenjeni upotrebi u skladu s patentnim zahtjevima 1 ili 2, naznačeni time što je najmanje 10 % navedenih adherentnih stanica u fazi proliferacije.
Further, the compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like. 
Nadalje, spojevi prema ovom izumu mogu biti u neotopljenom ili otopljenom obliku s farmaceutski prihvatljivim otapalima poput vode, etanola i sličnog.
is 2 to 15 amino acid residues in length; and wherein the first and second polypeptides form a cross-over light chain-heavy chain pair. 
L, je duljine 2 do 15 ostataka amino kiseline; i pri čemu prvi i drugi polipeptidi tvore prijelazni par laki lanac-teški lanac.
A process of preparing the compound of Formula Ia as defined in Embodiment 60 which comprises reacting compound If of the structure with acetic anhydride in the presence of dimethylaminopyridine CH3CN to form reacting the above compound with a reducing agent that is an alkylsilyl hydride in the presence of an activating group that is a Lewis Acid and CH3CN to form compound I of the structure reacting the above compound with a base and then with (S)-propylene glycol, optionally adding seeds of compound Ia to the reaction mixture, in the presence of an organic solvent to form crystalline compound Ia 
oH ta (oblik (8)-P6) naznačen time da sadrži reakciju spoja If sa strukturom OAc- B' reakciju gornjeg spoja sa redukcijskim sredstvom koje je alkilsilil hidrid u prisutnosti aktivirajuće skupine koja je Lewisova kiselina i CH3CN da se dobije spoj I sa strukturom reakciju gornjeg spoja sa bazom i zatim sa (S)-propilen glikolom, uz proizvoljno dodavanje zametaka spoja Ia u reakcijsku smjesu, u prisutnosti organskog otapala da se dobije kristalni spoj Ta 17.
so that the surplus of Liquefied Natural Gas from half maximum send-out, bypasses the re-condenser via a flow control bypass (24) which comprises at least one flow control bypass valve (4). 
regulator protoka (6) koji sadrži barem jedan ventil za kontrolu razine (3) za kontrolu razine ukapljenog prirodnog plina u donjoj akumulacijskoj zoni (12); naznačen time da sustav nadalje sadrži:
deprotecting Compound X to obtain Compound VII or converting Compound X directly to Compound I, wherein Compound IX and X are as follows: 
uklanjanje zaštite Spoja X radi dobivanja Spoja VII ili pretvorba Spoja X izravno u Spoj I, gdje su Spoj IX i X kako slijedi:
an oiler or nebuliser (30) for nebulising an odorising/aromatising liquid (L) and mixing it with the gas mixture (G1+G2) produced and fed by the mixing system (20); and 
- uljilo ili atomizer (30) za atomiziranje odorizirajuće/aromatizirajuće tekućine (L) 1 njeno miješanje sa smjesom plinova (G1+G2) koju proizvodi i opskrbljuje sustav miješanja (20); i